Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob D Soumerai

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Seminars in Hematology|April 15, 2026
Developing MRD as an early endpoint for accelerated approval in CLLJacob D Soumerai, William G Wierda
Hematology/Oncology Clinics of North America|July 24, 2025
Triplet Therapies in Chronic Lymphocytic LeukemiaJacob D Soumerai, Matthew S Davids
Cancer Control : Journal of the Moffitt Cancer Center|October 14, 2014
Diagnosis and management of Castleman diseaseJacob D Soumerai, Aliyah R Sohani, Jeremy S Abramson
Leukemia & Lymphoma|October 6, 2023
Combined analysis of the impact of second-generation BTK inhibitors on patient outcomesRobert A Redd, Josie Ford, Matthew Lei, et al.
Blood|May 14, 2011
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabSteven P Treon, Jacob D Soumerai, Zachary R Hunter, et al.
Leukemia & Lymphoma|February 3, 2022
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphomaThaís Fischer, Andy Ni, Kurt S Bantilan, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Hematological Oncology|October 5, 2023
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphomaHazim S Ababneh, Andrea K Ng, Jeremy S Abramson, et al.
Leukemia & Lymphoma|January 31, 2024
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaMatthew M Lei, Mark N Sorial, Uvette Lou, et al.
Leukemia & Lymphoma|July 16, 2020
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphomaJacob D Soumerai, Andy Ni, Anna Alperovich, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Seminars in Hematology|April 15, 2026
Developing MRD as an early endpoint for accelerated approval in CLLJacob D Soumerai, William G Wierda
Hematology/Oncology Clinics of North America|July 24, 2025
Triplet Therapies in Chronic Lymphocytic LeukemiaJacob D Soumerai, Matthew S Davids
Cancer Control : Journal of the Moffitt Cancer Center|October 14, 2014
Diagnosis and management of Castleman diseaseJacob D Soumerai, Aliyah R Sohani, Jeremy S Abramson
Leukemia & Lymphoma|October 6, 2023
Combined analysis of the impact of second-generation BTK inhibitors on patient outcomesRobert A Redd, Josie Ford, Matthew Lei, et al.
Blood|May 14, 2011
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabSteven P Treon, Jacob D Soumerai, Zachary R Hunter, et al.
Leukemia & Lymphoma|February 3, 2022
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphomaThaís Fischer, Andy Ni, Kurt S Bantilan, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Hematological Oncology|October 5, 2023
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphomaHazim S Ababneh, Andrea K Ng, Jeremy S Abramson, et al.
Leukemia & Lymphoma|January 31, 2024
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaMatthew M Lei, Mark N Sorial, Uvette Lou, et al.
Leukemia & Lymphoma|July 16, 2020
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphomaJacob D Soumerai, Andy Ni, Anna Alperovich, et al.
Pageof 5